Cargando…

Fremanezumab for migraine prevention: more effective, less costly

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256335/
https://www.ncbi.nlm.nih.gov/pubmed/32501385
http://dx.doi.org/10.1007/s40274-020-6852-z
_version_ 1783539888142942208
collection PubMed
description
format Online
Article
Text
id pubmed-7256335
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-72563352020-05-29 Fremanezumab for migraine prevention: more effective, less costly PharmacoEcon Outcomes News Meeting Report Springer International Publishing 2020-05-30 2020 /pmc/articles/PMC7256335/ /pubmed/32501385 http://dx.doi.org/10.1007/s40274-020-6852-z Text en © Springer International Publishing AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Meeting Report
Fremanezumab for migraine prevention: more effective, less costly
title Fremanezumab for migraine prevention: more effective, less costly
title_full Fremanezumab for migraine prevention: more effective, less costly
title_fullStr Fremanezumab for migraine prevention: more effective, less costly
title_full_unstemmed Fremanezumab for migraine prevention: more effective, less costly
title_short Fremanezumab for migraine prevention: more effective, less costly
title_sort fremanezumab for migraine prevention: more effective, less costly
topic Meeting Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256335/
https://www.ncbi.nlm.nih.gov/pubmed/32501385
http://dx.doi.org/10.1007/s40274-020-6852-z